-
Evelo Biosciences Inc NASDAQ:EVLO Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Location: | Website: www.evelotx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
16.69M
Cash
17.26M
Avg Qtr Burn
-18.43M
Short % of Float
1.18%
Insider Ownership
0.14%
Institutional Own.
12.86%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EDP1815 Details Atopic dermatitis | Failed Discontinued | |
EDP1815 Details COVID-19 | Failed Discontinued | |
EDP1815 Details Psoriasis | Failed Discontinued | |
EDP1867 Details Atopic dermatitis | Failed Discontinued | |
EDP2939 Details Psoriasis | Failed Discontinued |